Table 2.

Treatments and outcomes of COVID-19 patients.

	All patients (n = 70)	Local resident group (n = 16)	Traveler group (n = 54)	P
Oxygen inhalation, n (%)	38 (54.3)	10 (62.5)	28 (51.9)	.453
Mechanical ventilation, n (%)	9 (12.9)	3 (18.8)	6 (11.1)	.423
Glucocorticoid therapy, n (%)	12 (17.1)	3 (18.8)	9 (16.7)	.846
Anti-virus treatment, n (%)
Lopinavir/Ritonavir	38 (54.3)	7 (43.8)	31 (57.4)	.335
Darunavir/Cobicistat	9 (12.9)	3 (18.8)	6 (11.1)	.423
Lopinavir/Ritonavir and Arbidol	12 (17.1)	2 (12.5)	10 (18.5)	.575
Lopinavir/Ritonavir and Chloroquine	4 (5.7)	2 (12.5)	2 (3.7)	.183
Arbidol and Darunavir/Cobicistat	5 (7.1)	1 (6.3)	4 (7.4)	.875
Arbidol and Ribavirin	2 (2.9)	1 (6.3)	1 (1.9)	.354
ICU admission, n (%)	8 (11.4)	3 (18.8)	5 (9.3)	.295
Hospital stay, day, median (range)	13 (7, 60)	11 (8, 34)	14.5 (7, 60)	.749
Mortality, n (%)	3 (4.3)	1 (6.3)	2 (3.7)	.659

ICU = intensive care unit.